Shoeshine
|
Friday 14th November 2003 |
Text too small? |
The issues are old ones. First, the company didn't live up to the 2001 information memorandum ebitda (earnings before interest, tax, depreciation and amortisation) forecast of $18.3 million for the August 2002 year.
That's disappointing for everyone but in the context of a rocketing exchange rate, low beef prices for Tru-Test's customers and the Australian drought, it's scarcely surprising.
The Neuronz purchase has also aggravated some shareholders but, like the company's financial performance, that was known before last year's annual meeting, at which, apparently, no questions were asked.
The theory getting most traction is that someone is trying to unsettle shareholders and turn up the gas on Tru-Test's board and management to smooth the path of a takeover.
The natural candidate for the bidder is Skellmax Industries, whose largest shareholder, Axa Asia Pacific, has 5.67%.
It's a small country. Axa is also one of Tru-Test's shareholders.
No comments yet
PEB - Advancing Medicare Coverage Goals; Cost Contained
TRU - TruScreen Completes Oversubscribed Placement
EROAD Continues Transformation, Reports FY26 Results
May 25th Morning Report
EROAD Appoints New Director Progressing Board Renewal
OCA delivered record full year result
BLT - Strong revenue and underlying earnings growth
MFB - Food Bag reports full year profitability up 5.3%
TWR - Tower reports strong HY earnings
IPL - FY26 Annual Results